羟基脲用于尼日利亚镰状细胞贫血儿童卒中二级预防:一项随机对照试验
在尼日利亚开展的3期双盲平行组随机对照试验中,101例镰状细胞贫血(SCA)患儿随机接受低剂量(10 mg/kg/日,n=49)或中剂量(20 mg/kg/日,n=52)羟基脲治疗以预防卒中复发。中位随访1.6年(四分位距1.0-2.3),计划最短随访3.0年。低剂量组与中剂量组分别发生6例复发性卒中和2例死亡 vs 5例复发性卒中和3例死亡,主要结局(卒中或死亡)发生率比IRR为0.98(95%CI 0.32-3.00;P=.97),因无临床差异试验提前终止。
要点
- 低剂量与中剂量羟基脲组卒中或死亡发生率无显著差异(IRR 0.98;95%CI 0.32-3.00;P=.97)。
- 复发性卒中发生率低剂量组7.1 vs 中剂量组6.0/100人年(IRR 1.18;95%CI 0.30-4.88;P=.74)。
- 无参与者因骨髓抑制而停用羟基脲治疗。
核心结论
- 对于无法获得定期输血治疗的低收入环境中的镰状细胞贫血患儿,初始低剂量羟基脲是已知最低有效剂量的卒中二级预防方案。
- 低剂量与中剂量羟基脲组主要结局发生率无临床差异,试验因此提前终止。
研究设计与样本
- 3期双盲、平行组、随机对照试验,在尼日利亚镰状细胞贫血患儿中比较固定口服中剂量羟基脲(20 mg/kg/日)与固定口服低剂量羟基脲(10 mg/kg/日)用于卒中二级预防的初始治疗。
- 共101例参与者随机分配至低剂量组(n=49)和中剂量组(n=52)。
- 中位随访1.6年(四分位距1.0-2.3),计划最短随访3.0年。
主要发现
- 低剂量组发生6例复发性卒中和2例死亡,中剂量组发生5例复发性卒中和3例死亡。
- 主要结局(卒中或死亡)的发生率比IRR为0.98(95%CI 0.32-3.00;P=.97)。
- 复发性卒中发生率低剂量组为7.1/100人年 vs 中剂量组为6.0/100人年(IRR 1.18;95%CI 0.30-4.88;P=.74)。
- 作为口服羟基脲治疗依从性指标,低剂量组与中剂量组退还药片百分比中位数分别为3.0%和2.6%。
- 无参与者因骨髓抑制而停用羟基脲治疗。
临床怎么用
- 对于无法获得定期输血治疗的低收入环境中的镰状细胞贫血患儿,初始低剂量羟基脲是已知最低有效剂量的卒中二级预防方案。
局限性
- 试验因主要结局发生率无临床差异而提前终止。
- 中位随访1.6年(四分位距1.0-2.3),短于计划最短随访3.0年。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We tested the hypothesis that fixed oral moderate-dose hydroxyurea (20 mg/kg per day) for initial treatment of secondary stroke prevention results in an 80% relative risk reduction of stroke or death when compared with fixed oral low-dose hydroxyurea (10 mg/kg per day) in a phase 3 double-blind, parallel-group, randomized controlled trial in children with sickle cell anemia (SCA) living in Nigeria. A total of 101 participants were randomly allocated to low-dose (n = 49) and moderate-dose (n = 52) hydroxyurea treatment groups. The median participant follow-up was 1.6 years (interquartile range, 1.0-2.3), with a planned minimum follow-up of 3.0 years. A total of 6 recurrent strokes and 2 deaths vs 5 recurrent strokes and 3 deaths occurred in the low- and moderate-dose groups, respectively. The incidence rate ratio (IRR) of the primary outcome measure of stroke or death in the low- and moderate-dose hydroxyurea treatment groups was 0.98 (95% confidence interval [CI], 0.32-3.00; P = .97). The trial was stopped early owing to no clinical difference in the incidence rates of the primary outcome measure. The incidence rates of recurrent strokes were 7.1 and 6.0 per 100 person-years in the low- and moderate-dose groups, respectively, (IRR, 1.18; 95% CI, 0.30-4.88; P = .74). As a measure of adherence to the oral hydroxyurea therapy, the median percent of returned pills was 3.0% and 2.6% in the low- and moderate-dose groups, respectively. No participant had hydroxyurea therapy stopped for myelosuppression. For children with SCA in low-income settings without access to regular blood transfusion therapy, initial low-dose hydroxyurea is a minimum known efficacious dose for secondary stroke prevention.
引用
- Abdullahi SU, Sunusi S, Abba MS, et al. Hydroxyurea for secondary stroke prevention in children with sickle cell anemia in Nigeria: a randomized controlled trial. Blood. 2023. PMID: 36322937. doi:10.1182/blood.2022016620
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。